Chuangsheng Group Pharmaceutical-B (06628) received the first payment relating to the sale of CDMO assets

Zhitongcaijing · 5d ago

Zhitong Finance App News, Chuangsheng Group Pharmaceutical-B (06628) issued an announcement relating (including) to the sale of CDMO assets to the buyer (a wholly-owned subsidiary of WuXi Biologics) at a total cost of RMB 190 million. As of the date of this announcement, the Group has received the net amount of the initial payment of consideration from the buyer after tax in accordance with the terms of the asset purchase agreement. Proceeds collected will be used to supplement the Group's general working capital and develop the Group's product pipeline.

Due to the sale of CDMO assets, the Group's labor costs and operating expenses are expected to decrease in 2027 compared to 2026. The transfer of CDMO assets is ongoing, and the company expects to collect additional proceeds before the end of 2026, subject to the relevant terms and conditions of the asset purchase agreement.